

Title: Tyrosinase, could it be a missing link in ochronosis in alkaptonuria?

Authors: Adam M Taylor PhD, Vishnu Kammath & Aaron Bleakley.

Lancaster Medical School, Faculty of Health & Medicine, Lancaster University, Lancaster,
Bailrigg, LA1 4YW.

Corresponding author details:

Dr Adam M Taylor

Lancaster Medical School

Faculty of Health and Medicine

Lancaster University

Bailrigg

Lancaster

LA1 4YB

T: +44 (0) 1524 593131

Funding: Dr Taylor's work is kindly supported by the Rosetrees Trust.

ABSTRACT

The hypothesis that is proposed is that tyrosinase, an enzyme widely found within the human body is implicated in the ochronosis that occurs in alkaptonuria; an autosomal recessive condition first used by Archibald Garrod to describe the theory of "Inborn Errors of Metabolism." The disease results from the absence of a single enzyme in the liver that breaks down homogentisic acid; this molecule becomes systemically elevated in sufferers. The

condition is characterised by a clinical triad of symptoms; homogentisic aciduria from birth, ochronosis (darkening) of collagenous tissues (from ~30years of age) and ochronotic osteoarthropathy in weight bearing joints due to long term ochronosis in them (from ~40years of age). Tyrosinase, a polyphenol oxidase has been shown in many species to contribute to the darkening of tissues in many organisms; including humans in the production of melanin. Tyrosinase under the right conditions shows alterations in its substrate specificity and may contribute to the darkening seen in AKU where it moves away from polymerising tyrosine but also homogentisic acid, the causative molecule in alkaptonuria, that is present in excess.

INTRODUCTION

Alkaptonuria (AKU) is a rare autosomal recessive condition caused by a mutation in the gene coding for the enzyme Homogentisate 1,2 Dioxygenase (HGD), which breaks down homogentisic acid (HGA) in the tyrosine (TYR) metabolic pathway (1). The incidence of AKU worldwide is stated as being 1:250,000 individuals, however there are pockets of the world that show a much higher incidence with the Dominican Republic and Slovakia having an incidence of around 1:20,000 (2). There are at least 129 mutations reported in the HGD gene and all produce the AKU phenotype. There appears to be no correlation, currently, between the type of mutation and severity of the phenotype (3). The condition was first used by Archibald Garrod in 1908 to demonstrate the concept of “inborn errors of metabolism.” The condition displays a triad of clinical features; homogentisic aciduria which is present from birth, ochronosis of collagenous tissues which is believed to commence around the 3rd decade and progresses to cause the final feature which is ochronotic osteoarthropathy of weight bearing joints; due to the build-up of a polymeric derivative of HGA (1). The disorder sits on the TYR metabolic pathway with other conditions such as tyrosinaemia type-I which is fatal (4). However, AKU is not fatal and isn't associated with a shortened life span but sufferers display a much reduced quality of life as a consequence of the numerous co-

|

morbidities that arise, mainly due to the deposition of the ochronotic pigment in collagenous tissues, such as articular cartilages, heart valves and arterial vessel walls (5-7). In AKU the defective gene has been identified and located to chromosome 3q2 (8). A mouse model of the disease showing the lack of HGD has been detailed in the literature, but only recently was it shown to display the cartilaginous pigmentation synonymous with the human condition. Recent work has also shown that Nitisinone, a tri-ketone herbicide, is a potential therapy for AKU, work in a mouse model has shown a significant reduction of HGA (9) and early data from the latest human studies show that a similar effect is seen (10). Whilst there is an increase in the recent knowledge on the commencement of pigmentation in joints and the end stage of the disease, there is a gap in the knowledge on the intermediate steps that see the conversion of the monomer HGA to its destructive pigment polymer.

Our hypothesis is that an enzyme that is present in the body, tyrosinase, may be acting non-specifically using HGA as a substituted substrate following an alteration in physiological conditions due to the long-term elevation of HGA in the body.

HGA and TYR; their structure and function.

HGA, chemically known as 2,5-dihydroxyphenylacetic acid, is a *p*-diphenol and an intermediary in the breakdown of TYR. It is metabolised intracellularly by hepatocytes which produce the enzyme HGD that cleaves the benzene ring of the HGA molecule to give a linear structure; maleylacetoacetic acid which is then further metabolised. HGA is usually present in a non-alkaptonuric liver for fractions of a second and is usually undetectable in non-alkaptonurics (11). In AKU, HGA is rapidly oxidised to the intermediate benzoquinone acetic acid (BQA) (structure currently unknown). This quinone intermediate is then polymerised into ochronotic pigment. The pigmentation process seen in AKU is remarkably similar to that observed in the conversion of TYR to melanin in the body, a monomer (also a diphenol) is

polymerised to a quinone intermediary and finally a pigmented polymer; L-DOPA and melanin respectively (12).

The conversion of TYR to its quinone intermediary and then to melanin is the result of a single enzyme; tyrosinase which is the rate limiting enzyme in melanin synthesis. Currently the conversion of HGA to its quinone intermediary and polymeric pigment by an enzyme, if present, is not clear. It has previously been postulated that HGA polyphenol oxidases (HGA PPO's) catalyse the formation of ochronotic pigment from HGA. Zannoni identified that BQA was produced via the oxidation of HGA and that BQA may polymerise to form ochronotic pigment by these oxidative enzymes (13,14). However, scientists are still unable to identify HGA PPO's. It could be argued that their existence is questionable since they incur no survival advantage. In a healthy individual, HGA is oxidised to maleylacetoacetic acid, under the action of HGD, rendering HGA PPO's needless.

Physiological changes in AKU.

The physiological changes seen in AKU are well documented in relation to the presence of pigment in collagenous tissues and gram quantities of HGA excreted daily in the urine (15). The kidney appears to be a key factor in controlling the amount of HGA in the body system and removing it from the body, as renal function declines the amount of plasma HGA in the system increases (16). Renal function deteriorates with age and it may well be linked to the onset of deposition of HGA polymer in tissues as the ability or quantity of HGA removed from the body declines (17). It could be this reason why the onset of ochronosis is not seen in the paediatric or adolescent group. Further support for the involvement of the kidney is observed in a number of cases where individuals with AKU have experienced renal failure associated with rapidly progressing ochronosis (18-22).

The role of the kidneys in efficiently removing HGA is demonstrated in one of the few cases in the literature where a patient with AKU had undergone kidney replacement and demonstrated an almost 3 fold reduction in plasma HGA concentration; from 126.3 μ mol/L to 43.7 μ mol/L (23). Admittedly, there is data lacking on the pH changes seen in urine and plasma of AKU patients, but what little there is describes decreased urinary pH in AKU. This is reflective of the plasma pH and is also an indicator of renal tubular function (24).

The pigmentation process.

As described before, the pigmentation process shows remarkable similarities to the formation of melanin, yet relatively little is known about the intermediary(ies) between HGA and the ochronotic pigment. HGA is a small water soluble molecule and therefore is seen in tissues with a large amount of water, such as the articular cartilage (25). The affinity for deposition in collagenous tissues is widely accepted but the reason for deposition being seen here is not fully understood. It has been demonstrated that the periodicity of collagen appears to have an association with the deposition of pigment, but the exact site of nucleation on the collagen molecule or molecule associated with the collagen, is as yet unclear (26). The evaluation of ochronotic vs control cartilage by NMR spectroscopy has shown that there is a broadening of peaks for most molecules indicative of disorder in the tissue affecting most regions (27). However, the biggest question still not answered around the pigmentation process is “where does the pigmentation commence?”

Tyrosinase.

Tyrosinase is found in many living organisms including plants and bacteria and has been extracted and purified from a variety of them, its primary function is conversion of TYR to DOPA and then melanin. Numerous studies have observed the enzymes specificity and distribution; demonstrating tyrosinase to be a non-specific enzyme. It shows action against

other phenols, observed in a range of studies, some functionality was dependent upon the species which the tyrosinase originated from (28-32). These studies have mainly used monophenols and *ortho*-substituted diphenols as substrates. One study had used tyrosinase for the hydroxylation of *p*-substituted phenols (30), but there are currently no studies which use HGA as a substrate for tyrosinase. A further study showed that phenol could be converted by tyrosinase by as much as 93%, depending on the pH (pH 6.8) (33). Other studies have shown that different *ortho*-phenols can be used as alternative substrates for TYR in the production of melanin, with some of the phenols used being structurally similar to HGA (12). Mono-, di- and polyphenols have been tested to see if they are viable substrates, with results demonstrating that enzyme specificity was in part dependant on which organism tyrosinase originated from. However, the majority of enzymes displayed the ability to catalyse more than one substrate (34-36). Whilst studies in bacteria and plants are abundant, studies that use mammalian tyrosinase are limited. However there are studies emerging which demonstrate that mammalian tyrosinase also has low substrate specificity (37). These experiments offer potential that in the right physiological circumstances tyrosinase could act with HGA as its substrate, particularly in circumstances where HGA is in abundance, such as in AKU.

One question remains regarding the presence of tyrosinase in any of the tissues where ochronosis is seen. Ochronosis is observed in a variety of tissues including skin, sclera, heart valves and most commonly in cartilage and other connective tissues. Whilst these areas are specifically seen in AKU, other individuals not diagnosed with AKU can undergo exogenous ochronosis. Exogenous ochronosis occurs superficially in all skin types due to excessive use of hydroquinone cream for skin lightening therapy. In this form of therapy, the cream aims to inhibit tyrosinase activity in melanocytes, thus inhibiting melanin production (38-40). As well as skin, studies have also shown the presence of melanocytes in cardiac tissue (41). Considering the presence of tyrosinase within melanocytes, this further supports the theory

that tyrosinase is potentially the HGA PPO referred to by Zannoni that may be acting non-specifically (13, 42, 43). Recent work has shown that joint and connective tissues that are affected most commonly in AKU, including cartilage, demonstrate expression of enzymes on the TYR metabolic pathway (44, 45).

DISCUSSION

The ochronosis that occurs in AKU still presents a number of unanswered questions and each of these offers an alternative therapeutic opportunity. The fact that ochronosis takes a number of years to occur, well into adulthood, adds weight to the theory that there is a physiological change that promotes or precipitates the conversion of HGA to its ochronotic polymer. This is likely related to a reduction in kidney function with ageing but there are other factors that could play a role; evidence of the importance of cellular stress and polymerisation potentially marking damage to tissues appear to be associated with the pigmentation process (25, 46, 47, 48).

There is clearly a biochemical setting that allows for the natural conversion of HGA to ochronotic pigment, as seen in the urine of alkaptonuric patients (1). However this is unlikely to be the sole factor.

The potential for “natural” conversion of HGA to ochronotic pigment in the most severely affected tissue; cartilage at a rate similar to that seen in urine is unlikely. Given that HGA is elevated from birth and the effects of ochronotic pigment in cartilage is not seen for multiple decades shows that there is either a protective mechanism in cartilage or other pigment forming promoter mechanisms that are only activated in certain physiological circumstances. If the natural oxidation of HGA is the reason for the build-up of ochronotic pigment in cartilage, data seen in urine suggests that oxidation occurs straight away. If that is the case then why does arthropathy present in later life? Shouldn't ochronotic pigment be seen from

an early age? An explanation for this may be the fact that cartilage is avascular, so the tissue remains hypoxic so not much oxidation can occur. It is only when the patient ages, when there is an increase in inflammatory processes and an increase in free radicals in cartilage which may allow the oxidation of HGA leading to the formation of the ochronotic polymer. However, some studies have shown that the structure of ochronotic pigment is completely absent of inflammatory infiltrates (49).

A recent case report detailing AKU and acidosis had fatal complications, but a number of clinical details are of significance. The patient demonstrated marked skin darkening, indicative of ochronosis 7 days after admittance to hospital (50). This rapid progression of darkening of the skin is not usually seen in natural progression of AKU. The metabolic acidosis seen in this patient would likely not promote the natural oxidation of HGA as is seen in alkali environments such as urine. One could speculate that the rapid darkening in the skin and the acidic physiological setting in this patient may allow for the acidic environment to alter the specificity of tyrosinase to polymerise HGA. This has been described previously with tyrosinase catalysing other phenolic compounds displaying structural similarities to HGA at an acidic pH (12, 33).

The importance of the kidneys and the physiology *in vivo* can be seen with evidence of 4 reported cases of acidosis and 3 reported cases with acute kidney injury reported in separate individuals with AKU, from the literature, all resulting in death (51). Whilst the kidneys and other physiological mechanisms appear protective (to a point), there are other potential mechanisms that may become activated during ageing or pathology and these warrant further investigation to offer the potential for further development of therapeutic strategies to treat AKU. One link missing from the literature would be an individual who suffered from both AKU and albinism and any information on the pathogenesis of AKU in this individual may provide further clues for any potential action for tyrosinase in the disease process in AKU.

The physiological changes and circumstances that affect the specificity of tyrosinase are clearly documented in the literature. These changes offer the potential for the enzyme to act as a factor in the polymerisation of HGA in AKU patients and the action of tyrosinase and its potentially contributory factor in the disease process warrant further investigation in vitro, by means of assay and in vivo via means of tissue specific examination of cells for the production of tyrosinase.

Acknowledgements

Dr Adam Taylor would like to acknowledge the Rosetrees Trust for funding. The funders had no role in the production or decision to submit this manuscript for publication

Conflict of interest

The authors declare no conflicts of interest.

References

1. Mistry JB, Bukhari M, Taylor AM. Alkaptonuria. *Rare Dis.* 2013 Dec 18;1:e27475. doi: 10.4161/rdis.27475.
2. Zatkova A. An update on molecular genetics of Alkaptonuria (AKU). *J Inherit Metab Dis.* 2011 Dec;34(6):1127-36.
3. Nemethova M, Radvanszky J, Kadasi L, et al. *Eur J Hum Genet.* 2016 Jan;24(1):66-72. Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on 'black bone disease' in Italy.
4. Taylor AM, Preston AJ, Paulk NK, et al. Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. *Osteoarthritis Cartilage.* 2012 Aug;20(8):880-6.
5. Taylor AM, Batchelor TJ, Adams VL, Helliwell TR, Gallagher JA, Ranganath LR.

Ochronosis and calcification in the mediastinal mass of a patient with alkaptonuria. *J Clin Pathol.* 2011 Oct;64(10):935-6.

6. Taylor AM, Wilson PJ, Ingrams DR, Helliwell TR, Gallagher JA, Ranganath LR. Calculi and intracellular ochronosis in the submandibular tissues from a patient with alkaptonuria. *J Clin Pathol.* 2010 Feb;63(2):186-8.

7. Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria--a review of surgical and autopsy pathology. *Histopathology.* 2008 Nov;53(5):503-12.

8. Pollak MR, Chou YH, Cerda JJ, et al. Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. *Nat Genet.* 1993 Oct;5(2):201-4.

9. Preston AJ, Keenan CM, Sutherland H, et al. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. *Ann Rheum Dis.* 2014 Jan;73(1):284-9

10. Ranganath LR, Milan AM, Hughes AT, et al. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. *Ann Rheum Dis.* 2014 Dec 4. pii: annrheumdis-2014-206033. doi: 10.1136/annrheumdis-2014-206033.

11. Davison AS, Milan AM, Hughes AT, Dutton JJ, Ranganath LR. Serum concentrations and urinary excretion of homogentisic acid and tyrosine in normal subjects. *Clin Chem Lab Med.* 2015 Feb;53(3):e81-3. doi: 10.1515/cclm-2014-0668.

12. Garcia-Molina Mdel M, Muñoz-Muñoz JL, Garcia-Molina F, García-Ruiz PA, Garcia-Canovas F, Action of tyrosinase on ortho-substituted phenols: possible influence on browning and melanogenesis. *J Agric Food Chem*, 2012. 60(25): p. 6447-53.
13. Mannoni A, Selvi E, Lorenzini S, et al. Alkaptonuria, ochronosis, and ochronotic arthropathy. *Semin Arthritis Rheum*, 2004. 33(4): p. 239-48.
14. Zannoni, V.G., N. Lomtevas, Goldfinger S. Oxidation of homogentisic acid to ochronotic pigment in connective tissue. *Biochim Biophys Acta*, 1969. 177(1): p. 94-105.
15. Hughes AT, Milan AM, Christensen P, et al. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2014 Jul 15;963:106-12.
16. Hamdi N1, Cooke TD, Hassan B. Ochronotic arthropathy: case report and review of the literature. *Int Orthop*. 1999;23(2):122-5.
17. Weinstein JR, Anderson S. The Aging Kidney: Physiological changes. *Adv Chronic Kidney Dis*. 2010 Jul; 17(4): 302–307.
18. Kazancioglu R, Taylan I, Aksak F, et al. Alkaptonuria and renal failure: a case report. *J Nephrol*. 2004 May-Jun;17(3):441-5.
19. Venkataseshan VS, Chandra B, Graziano V, et al. Alkaptonuria and renal failure: a case report and review of the literature. *Mod Pathol*. 1992 Jul;5(4):464-71
20. Heng AE, Courbebaisse M, Kemeny JL, et al. Hemolysis in a patient with alkaptonuria and chronic kidney failure. *Am J Kidney Dis*. 2010 Jul;56(1):e1-4.
21. Bataille S, Moal V, Aquaron RR, Grünfeld JP, Daniel L. Hemolysis: a fatal complication of alkaptonuria in a severe renal failure patient. *Clin Nephrol*. 2014 May;81(5):374-6

- 22.. Isa Y, Nihei S, Irifukuhama Y, et al. A rare case of acquired methemoglobinemia associated with alkaptonuria Intern Med. 2014;53(16):1797-800.
23. Introne WJ, Phornphutkul C, Bernardini I, McLaughlin K, Fitzpatrick D, Gahl WA. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab. 2002 Sep-Oct;77(1-2):136-42.
24. Chernecky, C. C., & Berger, B. J. (2013). Laboratory tests and diagnostic procedures. St. Louis, Mo, Elsevier/Saunders.
25. Taylor AM, Boyde A, Wilson PJ, et al. The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheum. 2011 Dec;63(12):3887-96
26. Taylor AM, Wlodarski B, Prior IA, et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology (Oxford). 2010 Jul;49(7):1412-4.
27. Chow WY, Taylor AM, Reid DG, Gallagher JA, Duer MJ. Collagen atomic scale molecular disorder in ochronotic cartilage from an alkaptonuria patient, observed by solid state NMR. J Inherit Metab Dis. 2011 Dec;34(6):1137-40.
28. McMahon, A.M., E.M. Doyle, O'Connor K.E., Detection and quantification of 4-substituted phenols: a comparison of mushroom tyrosinase and cell extracts of *Pseudomonas putida* F6. Enzyme and Microbial Technology, 2005. 36(5-6): p. 808-812.
29. Selinheimo E, NiEidhin D, Steffensen C, et al. Comparison of substrate specificity of tyrosinases from *Trichoderma reesei* and *Agaricus bisporus*. Enzyme and Microbial Technology, 2009. 44(1): p. 1-10.

30. Munoz-Munoz JL, Berna J, García-Molina Mdel M, et al. Hydroxylation of p-substituted phenols by tyrosinase: further insight into the mechanism of tyrosinase activity. *Biochem Biophys Res Commun*, 2012. 424(2): p. 228-33.
31. Girelli AM, Mattei E, Messina A. Phenols removal by immobilized tyrosinase reactor in on-line high performance liquid chromatography. *Anal Chim Acta*, 2006. 580(2): p. 271-7.
32. Shesterenko YA, Sevast'yanov OV, Romanovskaya II, Removal of phenols from aqueous solutions using tyrosinase immobilized on polymer carriers and inorganic coagulants. *Journal of Water Chemistry and Technology*, 2012. 34(2): p. 107-111.
33. Seetharam GB, Saville BA, Degradation of phenol using tyrosinase immobilized on siliceous supports. *Water Research*, 2003. 37(2): p. 436-440.
34. Faccio G, Kruus K, Saloheimo M, Thöny-Meyer L. Bacterial tyrosinases and their Applications. *Process Biochemistry*. 2012;47(12):1749-60.
35. Zhang X, van Leeuwen J, Wichers HJ, Flurkey WH. Characterization of Tyrosinase from the Cap Flesh of Portabella Mushrooms. *Journal of Agricultural and Food Chemistry*. 1999;47(2):374-8.
36. Selinheimo E, Gasparetti C, Mattinen M-L, Steffensen CL, Buchert J, Kruus K. Comparison of substrate specificity of tyrosinases from *Trichoderma reesei* and *Agaricus bisporus*. *Enzyme and Microbial Technology*. 2009;44(1):1-10.
37. Draelos ZD, Raab S, Yatskayer M, Chen N, Krol Y, Oresajo C. A method for maintaining the clinical results of 4% hydroquinone and 0.025% tretinoin with a cosmeceutical formulation. *Journal of drugs in dermatology : JDD*. 2015;14(4):386-90.
38. Olivares C, Jimenez-Cervantes C, Lozano JA, Solano F, Garcia-Borron JC. The 5,6-dihydroxyindole-2-carboxylic acid (DHICA) oxidase activity of human tyrosinase. *The Biochemical journal*. 2001;354(Pt 1):131-9.
39. Rosen JR, Rosen ML, Kartsonis JP, Rosen LB. Endogenous ochronosis in dermal

melanocytic nevi: diagnosis of alkaptonuria by skin biopsy. *Journal of cutaneous pathology*. 2014;41(12):897-900.

40. Nagler A, Hale CS, Meehan SA, Leger M. Exogenous ochronosis. *Dermatology online journal*. 2014;20(12).

41. Yajima I, Larue L. The location of heart melanocytes is specified and the level of pigmentation in the heart may correlate with coat color. *Pigment Cell & Melanoma Research*. 2008;21(4):471-6.

42. Niwano T, Terazawa S, Nakajima H, Wakabayashi Y, Imokawa G. Astaxanthin and withaferin A block paracrine cytokine interactions between UVB-exposed human keratinocytes and human melanocytes via the attenuation of endothelin-1 secretion and its downstream intracellular signaling. *Cytokine*. 2015;73(2):184-97.

43. Van Raamsdonk CD, Deo M. Links between Schwann cells and melanocytes in development and disease. *Pigment Cell & Melanoma Research*. 2013;26(5):634-45.

44. Taylor AM, Wilson PJM, Fraser WD, Ranganath LR, Gallagher JA, Studies on the Deposition of Ochronotic Pigment in Alkaptonuria Reveal Tyrosine Metabolism in Human Chondrocytes. *Journal of Bone and Mineral Research*, 2008. 23: p. 374 - 505.

45. Laschi M, Tinti L, Braconi D, et al. Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. *J Cell Physiol*. 2012 Sep;227(9):3254-7.

46. Braconi D, Bianchini C, Bernardini G, et al. Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. *J Inherit Metab Dis*. 2011 Dec;34(6):1163-76.

47. Braconi D, Millucci L, Ghezzi L, Santucci A. Redox proteomics gives insights into the role of oxidative stress in alkaptonuria. *Expert Rev Proteomics*. 2013 Dec;10(6):521-35.

48. Mistry JB, Jackson DJ, Bukhari M, Taylor AM. A role for interleukins in ochronosis in a chondrocyte in vitro model of alkaptonuria. *Clin Rheumatol*. 2015 Oct 16. [Epub ahead of print]
49. Melis M, Onori P, Aliberti G, Vecci E, Gaudio E. Ochronotic arthropathy: structural and ultrastructural features. *Ultrastruct Pathol*, 1994. 18(5): p. 467-71.
50. Mullan A, Cocker D, Taylor G, Millar C, Ranganath L. Fatal oxidative haemolysis and methaemoglobinaemia in a patient with alkaptonuria and acute kidney injury. *Clin Kidney J*. 2015 Feb;8(1):109-12.
51. Davison AS, Milan AM, Gallagher JA, Ranganath LR. Acute fatal metabolic complications in alkaptonuria. *J Inherit Metab Dis*. 2015 Nov 23.